Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 9/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.99 |
| ▸ | CIT | O14578 | 1/20 | 0.99 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.99 |
| ▸ | GAK | O14976 | 1/20 | 0.99 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.99 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.99 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.99 |
| ▸ | STK17B | O94768 | 1/20 | 0.99 |
| ▸ | STK10 | O94804 | 1/20 | 0.99 |
| ▸ | ABL1 | P00519 | 1/20 | 0.99 |
| ▸ | LCK | P06239 | 1/20 | 0.99 |
| ▸ | FYN | P06241 | 1/20 | 0.99 |
| ▸ | YES1 | P07947 | 1/20 | 0.99 |
| ▸ | LYN | P07948 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canertinib SCHEMBL2141065 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL30436576 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29623482 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL54837 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29655741 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29368458 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL731396 | 0.98 | EGFR (0.97) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL3585133 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL30415948 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL13153156 | 0.92 | EGFR (0.86) | EGFRERBB2ERBB4KITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 858 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182864-A1 | NOVEL CHEMICAL COMBINATIONS AND METHODS OF USE THEREOF, TOWARDS DIFFERENTIATION OF HUMAN PROGENITOR CELLS INTO FUNCTIONAL BETA CELLS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2024-06-06 | — | — | US | claimed |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | GERO PTE LTD (SG) | 2023-06-22 | — | — | US | claimed |
| CN-109071622-B | Peptides with anticancer activity | IDP研发制药有限公司（ES） | 2023-01-13 | — | — | CN | claimed |
| WO-2022204377-A1 | NOVEL CHEMICAL COMBINATIONS AND METHODS OF USE THEREOF, TOWARDS DIFFERENTIATION OF HUMAN PROGENITOR CELLS INTO FUNCTIONAL β CELLS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-09-29 | — | — | WO | claimed |
| US-20040034022-A1 | Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride | GODECKE GMBH (DE) | 2004-02-19 | — | — | US | claimed |
| EP-1299363-A1 | POLYMORPHIC FORMS/HYDRATES OF N- 4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-(3-MORPHOLIN-4-YLPROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE DIHYDROCHLORIDE | GÖDECKE GMBH (DE) | 2003-04-09 | — | — | EP | claimed |
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | ELDER JAMES T (US) | 2002-11-14 | — | — | US | claimed |
| EP-1230919-A2 | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2002000630-A1 | POLYMORPHIC FORMS/HYDRATES OF N-[4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-(3-MORPHOLIN-4-YLPROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE DIHYDROCHLORIDE | Gödecke GmbH (DE) | 2002-01-03 | — | — | WO | claimed |
| EP-4748453-A2 | METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747408-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122081247-A | Oncolytic vaccinia virus and recombinant viruses and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260139315-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| EP-1299363-A1 | POLYMORPHIC FORMS/HYDRATES OF N- 4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-(3-MORPHOLIN-4-YLPROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE DIHYDROCHLORIDE | GÖDECKE GMBH (DE) | 2003-04-09 | — | — | EP | disclosed |
| EP-1299363-A1 | POLYMORPHIC FORMS/HYDRATES OF N- 4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-(3-MORPHOLIN-4-YLPROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE DIHYDROCHLORIDE | GÖDECKE GMBH (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | ELDER JAMES T (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1230919-A2 | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2002000630-A1 | POLYMORPHIC FORMS/HYDRATES OF N-[4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-(3-MORPHOLIN-4-YLPROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE DIHYDROCHLORIDE | Gödecke GmbH (DE) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000630-A1 | POLYMORPHIC FORMS/HYDRATES OF N-[4-(3-CHLORO-4-FLUOROPHENYLAMINO)-7-(3-MORPHOLIN-4-YLPROPOXY)-QUINAZOLIN-6-YL]-ACRYLAMIDE DIHYDROCHLORIDE | Gödecke GmbH (DE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | AGER, CKMT1A; CKMT1B, GLA | EGFR 1153/4885ERBB2 1599/4885ERBB4 1657/4885 |
| US-20020169176-A1 | Method for inhibiting retinoid skin damage | RARB, EBP, RXRA | EGFR 47/4885ERBB2 183/4885ERBB4 110/4885 |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | EGFR, ERBB2, HAVCR2 | EGFR 1/4885ERBB2 2/4885ERBB4 6/4885 |
| US-20260139315-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | APOL1, PDCD1LG2, PRSS1 | EGFR 264/4885ERBB2 1515/4885ERBB4 2040/4885 |
| US-20040034022-A1 | Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride | TP53, ABL1, PRKDC | EGFR 1887/4885ERBB2 234/4885ERBB4 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.